CL Stock Overview
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cresco Labs Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.67 |
| 52 Week High | CA$3.58 |
| 52 Week Low | CA$1.41 |
| Beta | 1.99 |
| 11 Month Change | -22.69% |
| 3 Month Change | -29.54% |
| 1 Year Change | -26.75% |
| 33 Year Change | -85.02% |
| 5 Year Change | -77.58% |
| Change since IPO | -74.50% |
Recent News & Updates
Recent updates
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely
Oct 24
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Aug 11Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?
Jul 17Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden
Jun 19Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 19Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41
Mar 16Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%
Mar 03Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt
Jan 26Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)
Jan 04Is Cresco Labs (CSE:CL) Using Too Much Debt?
Sep 22Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%
Aug 11Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet
Jan 25Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?
Dec 13We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt
Aug 22Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)
May 23Shareholder Returns
| CL | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -16.9% | -6.1% | 0.7% |
| 1Y | -26.8% | -22.3% | 21.7% |
Return vs Industry: CL underperformed the Canadian Pharmaceuticals industry which returned -22.8% over the past year.
Return vs Market: CL underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| CL volatility | |
|---|---|
| CL Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: CL's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: CL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,000 | Charlie Bachtell | www.crescolabs.com |
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy’s Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts.
Cresco Labs Inc. Fundamentals Summary
| CL fundamental statistics | |
|---|---|
| Market cap | CA$744.97m |
| Earnings (TTM) | -CA$94.28m |
| Revenue (TTM) | CA$1.02b |
0.6x
P/S Ratio-6.2x
P/E RatioIs CL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CL income statement (TTM) | |
|---|---|
| Revenue | US$726.35m |
| Cost of Revenue | US$360.10m |
| Gross Profit | US$366.26m |
| Other Expenses | US$433.69m |
| Earnings | -US$67.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 50.42% |
| Net Profit Margin | -9.28% |
| Debt/Equity Ratio | 116.3% |
How did CL perform over the long term?
See historical performance and comparison